Navigation Links
Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting
Date:12/6/2010

4;BSignaling and Induces Apoptosis in Multiple Myeloma Cells

Session: Myeloma – Pathophysiology and Preclinical Studies, excluding Therapy: Multiple Myeloma – Molecular Target-Based Therapy

Location: Orange County Convention Center, 314

About CK2 and CX-4945

Protein kinase CK2 has emerged as a validated drug target for cancer therapy due to its dysregulation andoverexpression in tumors and its regulatory roles in cell cycle control, DNA damage repair, and in the PI3K/Akt, JAK/STAT, IL-6 and NF-κB signaling cascades.  These pathways have specific relevance in multiple myeloma progression and high levels of CK2 overexpression characterize the disease.  CX-4945 is a potent and highly selective, small molecule inhibitor of CK2 and is currently under evaluation as an orally administered single agent in a Phase I clinical trial in patients with solid tumors (including breast, prostate, pancreatic cancers and inflammatory breast cancer) and a separate Phase I trial in patients with multiple myeloma has recently been initiated.  During the solid tumor trial, CX-4945 has established favorable pharmacokinetic, pharmacodynamic and safety profiles.  Measurement of mechanism and tumor-related biomarkers in patients reveal that CX-4945 hits the CK2 target and down-modulates the PI3K/Akt pathway.  The pharmacokinetic and biomarker data demonstrate that CX-4945 is achieving pharmacologically active levels in plasma and in tumor cells and elicits a clear pharmacodynamic response in humans.  Together, the findings establish CX-4945 as a promising therapeutic agent for targeting multiple cancers.

About Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. is a San Diego-based, private biotechnology company, discovering and developing targeted small molecule drugs to treat life-threatening cancers.  Cylene's drug discovery platform, STAND (Selective
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
2. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
3. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
4. GENFIT Selected by Windhover for the 2011 Top Biopharma Projects To Watch
5. PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santoprene™ TPV Medical Grades
6. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
7. CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference
8. The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
9. Neuronetics Selected by World Economic Forum as 2011 Technology Pioneer
10. Greenway Selected by Health Information Exchanges and Regional Physician Groups
11. Award-Winning Thermal Angel Selected as Winner for Outstanding Military Product of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)...  Volcano Corporation (Nasdaq: VOLC ), ... economic outcomes on a global basis by developing ... visualization, physiology diagnostics and therapies, today confirmed receipt ... from Engaged Capital, LLC.  The Company issued the ... welcomes the perspectives of its shareholders, and has ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... Summary GlobalData,s new report, "EU5 Esophagoscopes ... market data on the EU5 Esophagoscopes & Gastroscopes ... US dollars, volume (in units) and average prices ... Video Esophagoscopes, Flexible Non-Video (Fibre) Gastroscopes and Flexible ...
(Date:9/29/2014)... 29, 2014  Cancer Treatment Institute of ... new drug treatment: a carefully formulated, first-of-its-kind combination ... proven successful at treating multiple types of cancer. ... treatment are optimistic that it could significantly improve ... therapeutic avenues. "These two drugs are ...
Breaking Medicine Technology:Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 2EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020 3Cancer Treatment Institute of Colombia Demonstrates Unprecedented Results Using Unique Cancer Drug Combination of 3-Bromopyruvate and Salinomycin for Treatment of Multiple Types of Cancer 2Cancer Treatment Institute of Colombia Demonstrates Unprecedented Results Using Unique Cancer Drug Combination of 3-Bromopyruvate and Salinomycin for Treatment of Multiple Types of Cancer 3
... GPRO ) announced today that the Company ... investigational APTIMA(R) assay to detect human,papillomavirus (HPV), which ... multi-center study was an important goal,for Gen-Probe in ... and,chief operating officer. "Enrolling our first patient last ...
... Alone and in combination with, Ramipril Global Endpoint ... Annual Scientific Session of the American College of ... online in the New England Journal of Medicine, ... the landmark,ONTARGET(TM) trial have demonstrated that MICARDIS(R) (telmisartan), ...
Cached Medicine Technology:Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 2Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 3Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 4Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer 5Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 2Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 3Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 4Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 5Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 6Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population 7
(Date:9/30/2014)... September 30, 2014 For Dr. Jim Pertsch, ... in San Mateo, CA, the decision was simple. “I was ... when I heard Miele offered a solution for cleaning surgical ... for ways to help the staff, and the Miele system ... and I don’t worry as much about the staff coming ...
(Date:9/30/2014)... CE-Classes.com has announced the addition of ... for Healthcare Providers. This course on treating tobacco addiction ... - substance abuse counselors, social workers, professional counselors, psychologists, ... implementation of this new course” said Ron Black, president ... smoking has tremendous value to our society.” , Appropriate ...
(Date:9/29/2014)... September 30, 2014 Shoulder pain is one ... with persistent shoulder pain generates nearly ¾ of the total ... of all adults will experience shoulder pain, and of those ... also been reported that 1 in 4 people with either ... than a year. , “This is a real problem, not ...
(Date:9/29/2014)... 30, 2014 Foundations Recovery Network, an ... the start of its 40th national conference by hosting ... a featured keynote speaker at the Moments of Change ... in the fields of addiction and mental health treatment. ... Fla., September 29 – October 2, 2014, at The ...
(Date:9/29/2014)... Boston, MA A retrospective study led by ... found an overuse of colonoscopies for colorectal cancer ... commonly recommended shorter follow-up intervals than established guidelines ... subsequent colonoscopy overuse. , "Our study shows ... being performed too early, resulting in use of ...
Breaking Medicine News(10 mins):Health News:Introducing a Safe, Time-Saving Solution for Ambulatory Surgery Centers 2Health News:Introducing a Safe, Time-Saving Solution for Ambulatory Surgery Centers 3Health News:CE-Classes.com Introduces New Online Course for Healthcare Providers 2Health News:CE-Classes.com Introduces New Online Course for Healthcare Providers 3Health News:KORT Physical Therapist Shines a Light on Shoulder Pain and Latest Treatments 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Endoscopists recommend frequent colonoscopies, leading to its overuse 2
... , , WASHINGTON, July 9 The ... the work of the National Organization on Disability,s (N.O.D.) ... emergency managers and the disability community as the only ... and personnel experienced in emergency management and disability issues. ...
... 9 The ongoing recession and associated job cuts ... employee benefit plans, slowing health insurer growth and pressuring ... and Consulting. , , "Conning projects that health ... resulting in deteriorating margins through 2011," said Terence Martin, ...
... Hospital for Special Surgery have shown that a biodegradable scaffold ... knee cartilage. The study is unique in that it used ... to examine how the plug incorporated itself into the knee. ... meeting of the American Orthopedic Society for Sports Medicine, June ...
... ... the world,s leading manufacturer and distributor of automated blood pressure monitors and health testing ... ... 2009 -- Lifeclinic International has named Lon von Hurwitz Executive Vice President ...
... externally , THURSDAY, July 9 (HealthDay News) -- U.S. ... ear infections in children. , Antibiotics are typically used ... for children with recurrent ear infections. , "The emergence ... surgical procedure raise the need to develop different ways ...
... 9 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... devices worldwide, today announced that it will report its,financial ... after the U.S.,market closes on August 10, 2009. Mindray,s ... on August 11, 2009 U.S. Eastern Time (8:00 PM ...
Cached Medicine News:Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 2Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 3Health News:Conning Research: Health Insurance Industry Premium Growth and Profitability Under Pressure Through 2011 2Health News:Study identifies potential fix for damaged knees 2Health News:Study identifies potential fix for damaged knees 3Health News:Pioneer of Digital Place-Based Media Joins World's Leading Blood Pressure and Health Kiosk Manufacturer 2Health News:Vaccine May Someday Thwart Ear Infections 2Health News:Mindray to Report Second Quarter 2009 Financial Results on August 10, 2009 2
Curved shaft with flat 4.5 mm hook. Flat serrated handle with polished finish. Overall length: 5.3 inches....
... device allows for quick and ... ophthalmic surgical procedures. The "Quick ... through which a suture may ... during the loading procedure. The ...
Titanium. Small "H" shaped push-pull tip. Shaft angled 45 degrees, 9 mm from tip. Round knurled handle with dull finish. Overall length: 4.8 inches. Most popular size or model....
Left angled 5 mm blunt hook. Overall length: 9.9 inches....
Medicine Products: